%0 Journal Article
%T Somatic Alterations in TP53 and KRAS and Their Functional Impact in Epithelial Ovarian Cancer
%A Lucas Meyer
%A Anna Schmid
%A Stefan Braun
%J Asian Journal of Current Research in Clinical Cancer
%@ 3062-4444
%D 2025
%V 5
%N 2
%R 10.51847/WMTWAtDFtw
%P 211-225
%X In light of the bleak outlook for chemotherapy-resistant epithelial ovarian carcinoma (EOC) patients, we set out to corroborate the observations from an earlier whole-exome sequencing investigation by performing orthogonal Sanger sequencing on the identical patient cohort, along with an additional independent set of 127 EOC cases (n = 177, exclusively fresh frozen tumor specimens). Our emphasis was on TP53, a recurrently altered gene with implications for chemosensitivity, while KRAS was included as a supplementary therapeutic target; we further augmented the work with transcriptional expression data for both genes and assessed associations with clinical characteristics. Every TP53 and KRAS alteration uncovered by exome sequencing was verified. Individuals bearing KRAS mutations presented with a markedly higher prevalence of FIGO stages I or II (P = .002) and non-high-grade serous histological categories (nonHGSCs) (P 
%U https://galaxypub.co/article/somatic-alterations-in-tp53-and-kras-and-their-functional-impact-in-epithelial-ovarian-cancer-kftbyf0f4lw8zxw